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The kinetics, energetics, and structure of Cyclolinopeptide A binding with Human Serum Albumin were investigated with surface
plasmon resonance and circular dichroism. The complex is formed through slow recognition kinetics that is temperature sensitive
in the range of 20◦C–37◦C. The overall reaction was observed to be endothermic (ΔH = 204kJ mol
−1)a n de n t r o p yd r i v e n( ΔS =
746J mol
−1K
−1) with overall small changes to the tertiary structure.
1.Introduction
T h en u t r i t i o n a lb e n e ﬁ t so fLinum usitatissium seed, more
commonly known as ﬂaxseed, are of signiﬁcant interest
as ﬂax is seen as healthy [1]. Oil is the main constituent
of ﬂaxseed, with more than 70% of the oil composed
of polyunsaturated fat. Flaxseed oil is the richest source
of the essential omega-3 fatty acid, alpha-linolenic acid.
Biotechnology and biomedicine around ﬂax is developing
its nutraceutical potential and thus contributes to the value
added of the seed and oil [2–4]. Flaxseed is rich in nutrients,
such as lignans which have been shown in laboratory studies
tohelpprotectagainstcertaintypesofcancers[5–8].Inaddi-
tion, ﬂaxseed is a rich source of both soluble and insoluble
ﬁbers [1]. Flax also contains an abundance of hydrophobic
cyclolinopeptides (CLPs), identiﬁed as cycloinopeptides A-I
[9],totheextentthat500mgofCLPsareveryeasilyextracted
from 1000mL of pressed oil [10].
Cyclolinopeptide A (CLP-A), a nonapeptide with a
primary sequence of Pro-Pro-Phe-Phe-Leu-Ile-Ile-Leu-Val
shown in Figure 1, was ﬁrst isolated in 1959 from ﬂaxseed
oil precipitates [11]. The role of CLP-A and other CLPs
in ﬂax is unclear but in laboratory studies these peptides
exhibit potent immunosuppressive activity [12], as well as
inhibitory activity towards calcium-dependent activation of
T-lymphocyte cell division [13], as well as show antimalarial
activity [14].
Depending on the peptide sequence, CLPs may have an
abundance of C=O, N−H, and sulfur containing side chains,
which could be used for linking drug delivery vessels. For
instance, CLPs were synthesized with an even number of
D and L amino acids, and were found to stack through
intermolecular hydrogen bonding forming nanotubes with
an antiparallel structure [15]. The amino acid residues are
located on the exterior of the nanotube, which allows the
outer surface properties to be optimized to its environment
while the interior of the tube is uniform and adjustable by
the number of amino acid residues inserted in the peptide.
In another example, human serum albumin (HSA) was
modiﬁed with the cyclic-RGD peptide and a PEG linker was
used to link a previously “unlinkable” kinase inhibitor [16].
HSA is a globular protein and is the most abundant
protein present in the blood plasma commonly occur-
ring at concentrations of approximately 40mgmL−1.I t
is a transport protein due to its interactions with many
organic/inorganic compounds including fatty acids, giving it
an important function of regulating intercellular ﬂuxes [17].
HSA is composed of three structurally similar domains (I,
II, and III), each contain 2 subdomains (A and B) which are
stabilizedby17disulﬁdebridges.Inadditiontothe7binding2 Journal of Biomedicine and Biotechnology
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Figure 1: The structure of cyclolinopeptide A.
sites for fatty acids and a high aﬃnity binding site on the
N-terminus, there are two hydrophobic pockets (generally
referred to as site I and site II) located in subdomains IIA
and IIIA [18].
Investigation of the thermodynamics and kinetics of
CLP-A/HSA-binding and release is necessary when CLPs are
considered as a potential drug/nutraceutical ingredient, or
used as part of a potential nanodelivery device used for
delivering materials to a targeted environment in biomedical
applications.Here,wereportthebinding interactionofCLP-
A and HSA using surface plasmon resonance (SPR). Quanti-
tative association (Ka) and dissociation (Kd) constants were
obtained at diﬀerent temperatures, which also allowed the
determination of the thermodynamic parameters (ΔH, ΔG
and ΔS)[ 19]. Circular dichroism (CD) in both the near-UV
andfar-UVwasusedtoevaluateanyconformationalchanges
of HSA upon binding with the CLP-A [20].
2.MaterialsandMethods
2.1. Reagents. Amine coupling reagents (N-ethyl-N -(dim-
ethylaminopropyl)-carbodiimide (EDC), N-hydroxysuccin-
imide (NHS), Ethanolamine (EA)), HBS-EP (10mM
HEPES, 150mM NaCl, 0.005% surfactant p20 and 3.4mM
EDTAatpH7.4)andCM5carboxylateddextransensorchips
were obtained from Biacore (GE Healthcare, Montreal, QU).
HSA (fatty acid free) was obtained from Sigma (Oakville,
ON). All other chemicals and solvents used were reagent
grade.
CLP-A was extracted and puriﬁed from ﬂaxseeds using a
procedure previously reported [10]. Brieﬂy, ﬂaxseed (Linum
usitatissimum L. cv. Bethune) was extracted using a continu-
ous oilseed screw press (Komet, type CA59 C; IBG Monforts
Oekotec GmbH & Co. Germany). to release the ﬂaxseed oil.
The oil was ﬁltered, and placed under vacuum until CLP
extraction. Flaxseed oil was diluted with 5% ethyl acetate
in hexane, loaded on a silica-gel column, and CLP’s were
separated from the oil by successive elutions of 10% (v/v)
ethyl acetate in hexane, 50% ethyl acetate in hexane, 100%
ethyl acetate, 10% methanol in dichloromethane, and 20%
methanol in dichloromethane. The resulting CLPs extracted
from the ﬂaxseed oil were further separated by reverse-phase
HPLC using a gradient mixture of acetonitrile:water (30:70
(v/v)), and increasing the acetonitrile to 65% over 120min.
Fractions containing CLP-A were collected and freeze-dried.
Approximately 180mg of CLP-A was isolated per 1000mL of
ﬂaxseedoil.ThepurityofCLP-AwasconﬁrmedbyNMRand
mass spectrometry. The extracted CLP-A was recrystallized
in methanol prior to the SPR and CD experiments detailed
below.
2.2. Buﬀer and Analyte Preparation. Running buﬀer for all
experiments was prepared by diluting a 10X phosphate-
buﬀered saline (PBS) stock solution (100mM phosphate
buﬀer, 20.7mM KCl, 1370mMNaCl, pH 6.7) to a 1X PBS,
pH7.4solutioncontaining5%DMSO.Runningbuﬀerswere
ﬁltered and degassed daily before use.
Analyte solutions containing the CLP-A peptides were
prepared by diluting the stock solution (10mM in DMSO)
into 1.05X PBS, giving a ﬁnal 1X PBS, pH 7.4 buﬀer
containing 5% DMSO (same as the running buﬀer).
2.3. Surface Plasmon Resonance. All SPR measurements were
performedatdiﬀerent temperatures using a BiacoreX instru-
ment equipped with a research-grade CM5 carboxylated-
dextran sensor chip (Biacore). The ﬂuidic unit of the
instrument was cleaned prior to experiments using the DES-
ORB method (injections of 0.5% sodium dodecyl sulphate,
followed by 50mM glycine, pH 9.5) equipped in the instru-
ment’s software. On some occasions a “SUPER-CLEAN”
method was also used (injections of 1% CH3COOH, 1M
NaHCO3, 10mM HCl, and 6M GndHCl).
The carboxylated-dextran sensor chips were precon-
ditioned prior to HSA immobilization by priming the
instrument 3 times with HBS-EP buﬀer, followed by 3
successive 1min injections of 50mM NaOH at 50μLmin −1.
HSA was covalently immobilized onto a CM5 sensor surface
at 25◦C using standard amine-coupling chemistry [21]. Flow
cell 1 (Fc1) and ﬂow cell 2 (Fc2) were activated by a
7min injection of a 1:1 mixture of 0.1M NHS and 0.4M
EDC using a ﬂow rate of 5μLmin −1. Immediately after
activation, HSA (30μgmL −1,1 0m Ma c e t a t eb u ﬀer pH 5.3)
was immobilized onto Fc2. A 7min injection of 1M EA
(pH 8.5) was conducted over Fc1 and Fc2 to deactivate the
surfaces. The ﬁnal HSA concentration immobilized onto the
chip was 9–11kRU.
CLP-A solutions (50–200μM) were injected in triplicate
and ﬂowed over reference and HSA surfaces for 2min at a
ﬂ o wr a t eo f3 0μMmin −1, followed by a dissociation phase
of 3min for all experimental temperatures. At the end of
the CLP-A injection, the ﬂowing solution was switchedJournal of Biomedicine and Biotechnology 3
to the running buﬀer until the response returned to the
originalbaseline.Instanceswherethebaselinewasnotreadily
achieved, a short pulse of 50% (v/v) DMSO solution was
injected at high ﬂow rate to remove any remaining CLP-A.
Data were collected at a rate of 5Hz and processed using the
BiaEvaluation V4.2 software. The equilibrium constant, Ka,
was determined using the rectangular hyperbola equation
[20]:
Req = Rmax
Ka[CLP-A]
1+Ka[CLP-A]
,( 1 )
where Req, Rmax, [CLP-A] are the measured response values,
the binding site saturation value, and the concentration of
CLP-A, respectively. Curve-ﬁtting was done with Microcal
Origin V7.1 using a global Rmax value of 2000.
2.4. Circular Dichroism. CD measurements of HSA (18μM),
HSA/CLP-A (18μM, 50μM) in 10mM PBS, 5% DMSO, pH
= 7.4 buﬀer were made with a Pistar-180 CD spectrometer
(Applied Photophysics Ltd., Leatherhead, UK) at room
temperature. The far-UV region was scanned from 260–
180nm in 0.5nm steps at a scan rate of 10nmmin−1 and
a bandwidth of 6nm using a 0.010cm optical pathlength
quartz cuvette. The secondary structure was estimated using
the neural network deconvolution software CDNN V2.1
[22]. The near-UV region was scanned from 350–250nm in
0.5nm steps at a scan rate of 10nmmin−1, and a bandwidth
of 2nm using a 10 mm optical pathlength cuvette.
3. Results andDiscussion
Typical SPR response sensorgrams of CLP-A-binding inter-
action with HSA which was covalently immobilized onto a
carboxylated dextran gold-coated sensor surface via amine
coupling are shown in Figure 2. The response of CLP-A
for concentrations ranging between 50μM and 200μMa r e
shown at 20◦C, 25◦C, 30◦C, and 37◦C in Figures 2(a), 2(b),
2(c),a n d2(d), respectively. The gradual increase of response
to a steady state during CLP-A injection indicates very slow
recognition kinetics of the CLP-A to the HSA-binding site.
Quantitative kinetic data were initially extracted using the
kinetics proﬁling within the Biacore Evaluation software.
Increased concentration of CLP-A resulted in an increased
response suggesting that the saturation point of HSA was
not reached within the concentration range of CLP-A used.
The slow recognition and possible rate limiting step is due to
cyclic peptide becoming available for interaction with HSA.
The CLP-A has a large hydration sphere which dissociates
before interaction with HSA. This process requires energy
and also increases the entropy [19].
HSA has seven known fatty-acid-binding sites, each of
which is known to bind other types of small molecules
[17]. Two of the more common binding sites for small
molecule drugs are commonly known as Sudlow’s site I
(i.e. the warfarin-binding site), and Sudlow’s site II (the
benzodiazapene site). Entropy-driven Site I bound drug
molecules, which are structurally bulky, heterocyclic com-
pounds with centrally localized negative polar/charges and
Table 1: CLP-A/HSA equilibrium binding constants determined
from SPR sensorgrams.
Temperature (◦C) Ka
(a) (M−1) Kd
(b) (μM) χ2
20 757 (33) 1321 4.5
25 1687 (20) 593 1.9
30 7056 (36) 142 1.6
37 50032 (1792) 20 10.2
(a)determined from curve-ﬁtting dose-response curves (Figure 3)w i t h( 1).
The standard error from curve-ﬁtting are given in brackets.
(b)Kd = 1/Ka.
Table 2: Secondary structure evaluation from far-UV cirular
dichroism spectra.(a)
Secondary Structure HSA(b) (%) HSA/CLP-A(b) (%)
Helix 46 41
Antiparallel 8 9
Parallel 6 6
Beta-Turn 15 16
Rndm. Coil 27 29
Total Sum 102 101
(a)CDNN V2.1 software was used to evaluate the secondary structure using
the “complex” spectra category and the 210–260nm region of the spectra.
(b)HSA (18μM), and HSA/CLA (18μM, 50μM) were in in 10mM PBS, 5%
DMSO, pH = 7.4 buﬀer.
hydrophobic substitutions, have been suggested to bind
through hydrophobic interactions and/or must be bound in
a hydrophobic crevice within the binding cavity [23].
Dose-response curves taken at diﬀerent temperatures
are shown in Figure 3. CLP-A concentration was limited
to below 200μM due to the solubility of the peptide in
the buﬀer. The aﬃnity of interaction was estimated by ﬁrst
assuming that HSA-binding sites were equally available and
second that only high aﬃnity sites were occupied in the
working concentration range [24] .T h ed a t as e t ss h o w ni n
Figure 3 were ﬁt to (1), and the Ka and Kd values are
summarized in Table 1.T h eKd and Ka values indicate that
aﬃnity increases as the temperature increased. The shape
of the sensorgram as the temperature increases shows that
in addition to the increase in aﬃnity with temperature
there is also a change in recognition before steady state is
reached. The kinetic information shows that there is slower
association and faster dissociation at 25◦Cc o m p a r e dt ot h e
values at 37◦C. This suggests that there is larger binding
at the higher temperature. The faster release at the lower
temperaturesuggeststhatthermodynamicparameterswould
also be important in understanding this binding. The fast
dissociationat25◦Candtheslowerdissociationat37◦Cshow
that 12◦C change contribute signiﬁcantly to reaching the
activation energy. The larger binding at higher temperatures
indicates that the activation energy is relatively low. To fur-
ther elucidate the HSA/CLP-A interaction, thermodynamic
parameters are extracted using the van’t Hoﬀ equation
lnKd =
ΔH
R

1
T

−
ΔS
R
,( 2 )4 Journal of Biomedicine and Biotechnology
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Figure 2: Representative SPR sensorgram responses for CLP-A (50–200μM) binding to HSA at (a) 20◦C, (b) 25◦C, (c) 30◦C, (d) 37◦C.
Experiments performed at each temperature were independent experiments and each experiment was repeated.
where R = 8.314Jmol−1K
−1.Ap l o to fl nKd versus
T−1 shown in Figure 4 is linear. This yields ΔH and ΔS
for the interaction to be 204kJmol−1 and 746Jmol−1 K−1
respectively [19]. The binding is overall endothermic. This
indicates an association with the hydrophobic pockets of
HSA and the opening of binding sites. Moreover, DMSO
has been used to assist the solubility. Therefore, the entire
solvation complex consisting of CLP-A, DMSO and H2O
requires energy to expose the binding site. This energy
plus the binding energy for interaction in the hydrophobic
pockets of HSA result in an overallendothermic process. The
largeentropyoftheendothermicprocessclearlyindicatethat
binding is entropy-driven. This is due to contribution from
breaking of the solvation complex and hydrophobic binding.
Thermodynamic investigation of several anionic drug
binding to HSA has been reported. It was found that the
Site II bound drugs formed enthalpy driven complexes
(large-ΔH,l a r g e - ΔS) whereas Site I bound drugs produced
more entropy-driven complexes (small-ΔH, minimal neg-
ative or positive ΔS). Interestingly, the ΔG value for all
drug molecules was approximately constant (−30kJmol−1
at 37◦C) [25]. For the CLP-A HSA interaction, the calculated
ΔGisapproximately −27kJmol−1 (at37◦C),whichisslightly
lowercomparedtotheanionicdrugs.However,thisΔGvalue
is comparable to values reported for short-medium chain
(C4–C8) fatty acid-binding to HSA (−26 to −28kJmol−1
at 37◦C) [23]. These fatty acids were found to bind in only
one class of binding sites of HSA at a ratio of 2:1. The
binding process formed enthalpy driven complexes, reﬂect-
ing van der Waals and/or hydrogen binding in low dielectric
media.
Presently, it is unclear as to the role of individual amino
acids or possible sequence that play a primary role for
CLP-A’s binding with HSA. Research involving other CLPs
(CLP-B, CLP-E) and some of their modiﬁed counterparts is
currently ongoing. Previous studies involving the biologicalJournal of Biomedicine and Biotechnology 5
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Figure 3: Dose-response curves of CLP-A (50–250μM) binding to HSA at (a) 20◦C, (b) 25◦C, (c) 30◦C, (d) 37◦C. Curves were curve-ﬁtted
with (2)t oo b t a i nKa of the interaction. Error bars are the standard deviation taken from 3 measurements.
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Figure 4: Thermodynamic parameters for the CLP-A-binding
interaction to HSA are determined by the van’t Hoﬀ equation (3).
activity of this peptide has shown that the—Pro-Phe-Phe-
tripeptide block played an important role in its ability to
inhibit cholate uptake into hepatocytes [26]. Other studies
have found that the CLP-A has immunosuppressive activity
[12], and many structural analogues have been synthesized
to study the peptide sequence’s role [27]. It was concluded
thattheﬂexibilityofthepeptidestructureplaysanimportant
role in its biological function. Other work has focused on
increasing the solubility of CLP-A without suppressing its
biological activity [28]. It was determined that substitution
of the Phe residues with their sulfonated derivates for
CLP-A and its linear and cyclic derivatives maintained
their immunosuppresor activity. For the current study, it
could be speculated that increasing the solubility of CLP-A
would reduce the overall solvation complex, which would
reduce the thermodynamic parameters of the CLP-A/HSA
interaction.
Another interesting feature observed from the SPR data
was that the measured Req for a given concentration of6 Journal of Biomedicine and Biotechnology
200 210 220 230 240 250 260
−16
−12
−8
−4
θ
(
m
d
e
g
)
Wavelength (nm)
HSA
HSA/CLA
0
(a)
260 280 300 320 340
−25
−20
−15
−10
−5
θ
(
m
d
e
g
)
Wavelength (nm)
HSA
HSA/CLA
0
(b)
260 280 300 320 340
−3
−2
−1
0
1
2
3
4
θ
(
m
d
e
g
)
Wavelength (nm)
(c)
Figure 5: Circular dichroism spectra of HSA (18μM), and HSA/CLA (18μM, 50μM) in 10mM PBS, 5% DMSO, pH = 7.4 buﬀer taken in
the (a) far-UV and (b) near-UV spectral region. Spectra were an average of 4 spectra, and respective background spectra were subtracted
accordingly. (c) Diﬀerence CD spectrum of HSA (18μM), and HSA/CLA (18μM, 50μM) solutions for the near-UV region indicates some
conformational changes after CLP-A-binding.
CLP-A also increased with temperature. Given that the HSA
surface concentration was approximately 11kRU, one can
estimate that the theoretical Rmax for this binding interaction
is approximately 160RU using the relation:
Rtheoretical
max =
MWa
MWL
∗RL ∗Sm,( 3 )
where MWa,M W L are the molecular weights of the analyte
and ligand, respectively, RL is the surface density of ligand,
and Sm is the stoichiometry of the interaction. From (3),
the increase in the given response could be due to peptide
aggregation, or additional binding to other active binding
sites on the HSA. It should be noted that SPR is measuring
a change in the refractive index at the sensor surface, and
this will be aﬀected by temperature change, although it
should not be signiﬁcant in this narrow temperature range.
Conformational changes of proteins can also change SPR
responses [29].
In order to assess if any conformational changes were
present upon CLP-A complexation with HSA, we compared
the far-UV and near-UV CD spectra of HSA and HSA/CLP-
A in the running buﬀer used in the Biacore experiments
shown in Figure 5. CD spectra taken in the far-UV spectral
region provide insight to the secondary structure of a
protein. In Figure 5(a), we observe that the CD spectrum for
the HSA/CLP-A complex has a slightly diﬀerent lineshape
compared to the native HSA CD spectrum, suggesting that
there are slight changes to the secondary structure of HSA
upon CLP-A-binding. The secondary structure of HSA was
evaluated using the CDNN deconvolution software [22],
and the resulting secondary components are summarized in
Table 2. The secondary structure results indicate the α-helixJournal of Biomedicine and Biotechnology 7
content of HSA decreases slightly upon the binding of CLP-
AThere are also some signiﬁcant changes in the near-UV
CD spectra shown in Figure 5(b). This region of the spectra
corresponds to signals from the phenylalanine, tyrosine, and
tryptophan residues on the protein and it provides insight to
changes in the tertiary structure of the protein. The observed
change in CD signal indicates a tertiary conformational
change upon CLP-A-binding, shown in Figure 5(c).
4. Conclusions
The CLP-A/HSA interaction investigated by SPR shows the
complex is formed by a strong endothermic and entropy-
driven reaction. This entropy-driven complexation indicates
that the interaction occurs through a hydrophobic interac-
tion of the CLP-A and possibly Sudlow site I of the HSA.
Complex formation is through slow recognition kinetics
and is relative stable at physiological temperatures. A slight
change in both secondary and tertiary structure of HSA are
observeduponthebinding ofCLP-A.Althoughtherearestill
many potential questions that remain regarding the binding
of CLP-A to HSA, the fact that quantitative thermodynamic
and binding constants has been demonstrated can help lay
the foundation for the future development of any potential
biomedical applications involving CLP-A. This would add to
understanding the nutraceutical potential of CLP-A and CLP
in general.
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